Adaptive Biotechnologies IPO

Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.

Register for Details

For more details on financing and valuation of private companies similar to Adaptive Biotechnologies before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Adaptive Biotechnologies

To invest in Adaptive Biotechnologies pre-IPO

Can you invest in Adaptive Biotechnologies pre-IPO?

You may invest in Adaptive Biotechnologies as it is a public company listed on the NASDAQ with ticker ADPT. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Adaptive Biotechnologies before it goes public?

You can no longer sell shares of Adaptive Biotechnologies on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Adaptive Biotechnologies shares?

Forge can no longer determine the value of Adaptive Biotechnologies shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Adaptive Biotechnologies a publicly traded company?

Adaptive Biotechnologies became a public company following its IPO on 06/27/2019 and is now traded on the NASDAQ under the ticker ADPT.

To learn more about Adaptive Biotechnologies potential IPO

Will Adaptive Biotechnologies go IPO?

Adaptive Biotechnologies became a public company following its IPO on 06/27/2019 and is now traded on the NASDAQ under the ticker ADPT.

What is Adaptive Biotechnologies’ IPO price?

The IPO price of Adaptive Biotechnologies is not currently available.

When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009.

What is Adaptive Biotechnologies funding to date?

Adaptive Biotechnologies has raised $561.37MM to date.

Who are Adaptive Biotechnologies’s major investors?

Illumina
Matrix Capital Management
Viking Global Investors
Alexandria Real Estate Equities
Rock Springs Capital
Senator Investment Group
Casdin Capital
Foresite Capital Management
Celgene
Ares Capital
Microsoft
Undisclosed Investors
Laboratory Corporation Of America
Tiger Global Management
Angel Investors
Bd Biosciences

Adaptive Biotechnologies Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
01/04/2018 Series F-1 $45MM $xx.xx $1.35B Microsoft
Price per Share
$xx.xx
Shares Outstanding
4,217,985
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Microsoft
05/06/2015 Series F $195.1MM $xx.xx $1.08B Matrix Capital Management, Alexandria Real Estate Equities, BD Biosciences, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Casdin Capital, Viking Global Investors
Price per Share
$xx.xx
Shares Outstanding
21,761,676
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Matrix Capital Management, Alexandria Real Estate Equities, BD Biosciences, Celgene, Foresite Capital Management, Illumina, Laboratory Corporation of America, Matrix Capital Management, Rock Springs Capital, Senator Investment Group, Tiger Global Management, Casdin Capital, Viking Global Investors
01/22/2015 Series E1 $105.12MM $xx.xx $652.13MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
17,407,441
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors
01/21/2015 Series E $93.75MM $xx.xx $321.37MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
15,524,350
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors
07/29/2014 Series D $107MM $xx.xx $261.89MM Viking Global Investors
Price per Share
$xx.xx
Shares Outstanding
19,269,117
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viking Global Investors
07/09/2013 Series C $5.02MM $xx.xx $76.08MM Viking Global Investors, Ares Capital
Price per Share
$xx.xx
Shares Outstanding
1,905,206
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Viking Global Investors, Ares Capital
06/02/2011 Series B $5.82MM $xx.xx $49.04MM Angel investors
Price per Share
$xx.xx
Shares Outstanding
3,399,033
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Angel investors
03/24/2010 Series A $4.55MM $xx.xx $27.52MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
4,550,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors
Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.